Key facts
- AlgaeCytes’s last known valuation is $84.3M (Dec 2025).
- It has raised $28.1M; the latest was Later Stage VC ($4.3M) in Dec 2025.
- Notable investors include Innovate UK, Bundesministerium für Wirtschaft und Klimaschutz, BioProNET, IBG Beteiligungsgesellschaft Sachsen-Anhalt.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for AlgaeCytes
- ·The full record, as it builds
Funding rounds
No funding rounds for AlgaeCytes are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AlgaeCytes
Operator of a biotechnology company intended to offer health-promoting ingredients from algae. The company specializes in the production of omega oils and bio-actives from freshwater algae for healthcare, personal care, and nutraceutical markets, while reducing the reliance on limited fish stock for protein and oil supplements, enabling vegan consumers to avail of enhanced and organic products.
- Sector
- Materials and Resources
- HQ
- Kent, United Kingdom
- Founded
- 2010
- Employees
- 12
- Website
- algaecytes.com/
- Ownership
- Privately Held (backing)
AlgaeCytes doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AlgaeCytes shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AlgaeCytes in its N-PORT filings yet. We sweep new filings monthly.